BioCentury
ARTICLE | Financial News

InflaRx raises $55M in series D

October 13, 2017 9:14 PM UTC

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included a $30 million capital increase and a $25 million secondary share purchase. The company declined to respond to inquiries.

InflaRx plans to conduct a Phase IIb trial of IFX-1, a mAb against complement 5a (C5a), to treat chronic inflammatory and autoimmune diseases...

BCIQ Company Profiles

InflaRx N.V.

BCIQ Target Profiles

Complement 5a (C5a)